CS 2022 Plenary Sessions
It’s not often you can surround yourself with experts in your field who are as willing to engage with you as you are with them—not unless you attend DF’s annual Clinical Symposium. Year after year, the event gathers illustrious speakers as well as kudos. People come to converse, learn, and debate.
We’ve selected summaries of mini-symposia presentations delivered in 2022 by Dr. Tina Bhutani, Dr. Jeremy Bordeaux, Dr. Steven Chen, Dr. Yvonne Chiu, Dr. Mark Davis, Dr. Jeff North, and Dr. Jim Treat.
Mohs for Melanoma
Dr. Bordeaux’s key takeaway message is that Mohs decreases the local recurrence of melanoma and helps reduce the number of re-excisions that patients undergo due to positive margins
Dermatofibrosarcoma
NCCN recommends Mohs as the first-line therapy for DFSP
When to Suspect Immunodeficiency
Dr. Treat presented three types of clinical scenarios suggesting immunodeficiency: primary skin findings of infections that are unusual, opportunistic, or exuberant; secondary skin findings of eczematous or granulomatous changes; and immunosuppressed groups.
The Curious Syndrome of Erythromelalgia
Dr. Davis presented his medical experiences of patients with erythromelalgia. He typically sees 3-5 new patients with erythromelalgia per week.
New Insights from Genetic Analysis of Cutaneous Adnexal Tumors
Dr. North presented new insights from genetic analysis of cutaneous adnexal tumors.
Clues for Diagnosing Uncommon Inflammatory Diseases
Dr. North presented cases of uncommon inflammatory skin diseases and the clues for diagnosis.
Pediatric Connective Tissue Disease: Cases that Taught Me a Lesson
Dr. Chiu presented 4 cases of pediatric connective tissue diseases and the lessons learned from each case.
New Topical Therapies for Psoriasis and Atopic Dermatitis
Dr. Bhutani presented new topical therapies for psoriasis and atopic dermatitis, including tapinarof, roflumilast, and ruxolitinib.
Caring for the Patient with Cutaneous Immune-Related Events
Dr. Chen presented new research on the management of dermatologic immune-related adverse events (D-irAEs), including high-yield tips, and discussed potential future implications and therapeutic care of patients who receive immune checkpoint inhibitors (ICIs).